August 6, 2025Mayo Clinic Proceedings Innovations Quality & Outcomes1 citationsOpen Access

Routine Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials

MIMahmoud IsmaylMayo Clinic MMMusa MufarrihMayo Clinic MEMackram F. EleidInterventional Cardiology

Structured PICO

Does routine cerebral embolic protection reduce stroke, disabling stroke, or all-cause mortality in patients undergoing TAVR?

Population

Patients undergoing Transcatheter Aortic Valve Replacement (TAVR)

Intervention

Routine Cerebral Embolic Protection (CEP) during TAVR

Comparator

Control group (no CEP)

Outcome

Stroke, disabling stroke, or all-cause mortalityhard clinical

Routine use of cerebral embolic protection during TAVR does not significantly reduce the risk of stroke, disabling stroke, or all-cause mortality.

Abstract

=.64). There were no significant differences in all-cause mortality or safety outcomes between the CEP and control groups. Subgroup analyses based on the type of CEP device showed no significant differences in outcomes between the 2 groups, regardless of device type. In conclusion, routine CEP use during TAVR was not associated with reductions in stroke, disabling stroke, or all-cause mortality. Future studies are warranted to identify subgroups that may benefit from selective CEP use.

Ask AI

Helpful

Bookmark

View Full Paper